Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause Laboratory test abnormal? 233 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 233 reports of Laboratory test abnormal have been filed in association with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). This represents 2.2% of all adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.
233
Reports of Laboratory test abnormal with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
2.2%
of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN reports
11
Deaths
9
Hospitalizations
How Dangerous Is Laboratory test abnormal From LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?
Of the 233 reports, 11 (4.7%) resulted in death, 9 (3.9%) required hospitalization.
Is Laboratory test abnormal Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. However, 233 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause?
General physical health deterioration (4,332)
Ill-defined disorder (3,600)
Death (1,179)
Disease progression (286)
Malignant neoplasm progression (251)
Prostatic specific antigen increased (212)
Fatigue (177)
Anaemia (154)
Covid-19 (139)
Platelet count decreased (130)
What Other Drugs Cause Laboratory test abnormal?
LENALIDOMIDE (4,215)
CINACALCET (4,210)
POMALIDOMIDE (1,218)
ADALIMUMAB (845)
ETANERCEPT (753)
DALFAMPRIDINE (650)
PALBOCICLIB (550)
NIRAPARIB (536)
METHOTREXATE (507)
ECULIZUMAB (441)
Which LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Alternatives Have Lower Laboratory test abnormal Risk?
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTETIUM OXODOTREOTIDE LU-177
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTROPIN ALFA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYRICA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYSERGIDE